significant differences. The proportions of early mortality (0.3% vs. 0.1%; RR: 3,) and overall complications (5.1% vs. 6.3%, RR: 0.80, 95%CI: 0.46-1.38) was low and with no statistically significant differences in OPG vs. IPG patients. Additionally, the RRs for any of the reported specific complications (Table 1) were not significantly different across both groups.
INTRODUCTION AND OBJECTIVES: The Expanded Prostate
Cancer Index short form (EPIC-26) is a validated questionnaire for measuring health-related quality-of-life in men with prostate cancer. Responses to the 26 individual questions are aggregated into 5 domains, with domain scores reported as a measure of patient function. However, the relationship between domain score and specific functional outcomes remains unclear, leading to potential confusion about expectations after treatment. For instance, what does a sexual function domain score of 80 actually mean with regard to a patient being able to obtain an erection sufficient for intercourse? Resultantly, we sought to clarify the relationship between domain scores and individual questions reflecting clinically relevant outcomes.
METHODS: Utilizing data obtained from the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) Study, a multicenter, prospective study of men diagnosed with localized prostate cancer in 2011 to 2012, we analyzed the EPIC-26 from 2,138 men at 3 years of follow-up who were treated with either radical prostatectomy, radiotherapy, or active surveillance. We dichotomized every EPIC-26 questionnaire item into its best possible outcome (best vs. any other response) and assessed the percentage of men at each domain score who obtained the best result. RESULTS: Figure 1 highlights the relationship between domain scores and individual items and demonstrates the domain score below which optimal functional outcomes are less likely. For example, a score of 80 on the sexual function domain corresponded to 96% of men reporting an erection sufficient for intercourse whereas at 40, only 12% of men reported adequate erections. Meanwhile, at a score of 95 on the urinary incontinence domain, 100% of patients reported no leakage vs. 0% at a score of 50. Similarly, at a score of 95, 100% of patients reported no pads vs. only 30% at a score of 50.
CONCLUSIONS: Our findings show a novel way to interpret EPIC-26 domain scores and understand clinically meaningful differences. Our results suggest a particular change in domain score may have a differential impact on clinically relevant functional outcomes depending on the baseline domain score. This information may be valuable when counseling men preoperatively on treatment options.
Source of Funding: None

MP44-17 A NATIONAL SURVEY OF RADIATION ONCOLOGISTS AND UROLOGISTS ON PREDICTION TOOLS AND NOMOGRAMS FOR LOCALIZED PROSTATE CANCER
Boris Gershman, Providence, RI; Paul Maroni, Denver, CO; Jon Tilburt, Rochester, MN; Robert Volk, PhD, Houston, TX; Badrinath Konety, MD, Minneapolis, MN; Alexander Kutikov, MD, Marc Smaldone, Marc Smaldone, Philadelphia, PA; Victor Chen, Cleveland, OH; Simon Kim*, Denver, CO INTRODUCTION AND OBJECTIVES: Integration of prediction tools for prostate cancer (PCa) is essential to high quality treatment decisions and shared decision-making. Yet, little is known about the degree of confidence in existing tools and whether they are used in clinical practice from radiation oncologists (RO) and urologists (URO). Herein, we performed a national survey of specialists about perceived attitudes and use of prediction tools.
METHODS: In 2017, we surveyed 940 URO and 911 RO to query their confidence in and use of the D'Amico criteria, Kattan Nomogram, and CAPRA score from a 4-wave mailing. The statistical analysis involved bivariate association and multivariable logistic regression analyses to identify physician characteristics associated with survey response and use of active surveillance (AS) for lowrisk PCa.
RESULTS: Overall, 691 (37.3%) specialists completed the surveys with similar response rates from RO and URO (35.7% vs. 38.7%; p[.18 ). Two thirds (Range: 65.6% -68.4%) of respondents reported being "somewhat confident", but only a fifth selected "very confident" for each prediction tool (18.0% -20.1%). 19.1% of specialists in the survey reported not using any prediction tools in clinical practice, which was higher amongst URO than RO (23.9% vs. 13.4%; p < 0.001). Lack of using prediction tools was also associated with low use of AS (<5%) in their low-risk PCa patients (OR: 2.47; p [ 0.01).
CONCLUSIONS: While a majority of RO and URO view existing prediction tools for localized PCa with some degree of confidence, a fifth of specialists reported not using any such tools in clinical practice.
INTRODUCTION AND OBJECTIVES: African-American (AA) men are disproportionately affected by socio-economic factors that limit their access to care. AA men are also less likely to receive prostate cancer (PCa) screening, and when diagnosed with PCa, have an increased morbidity and mortality when compared to patients of other ethnicities. Despite controversy regarding PSA screening, it is not known if targeted screening in a high-risk population is valuable, or whether screening provides an opportunity for identification of other comorbid conditions. We designed a community-based and literacyappropriate PCa screening program, with attention to other general health concerns.
METHODS: The Prostate Screening and Cancer AwarenessNashville (P-SCAN) program invited men 40 and older who had never received PCa screening to receive education about the disease. Literature written at a sixth grade level was given to all participants, and they spoke with a nurse practitioner about the risks and benefits of screening. Patients who chose to undergo screening had PSA and digital rectal examination (DRE), as well as serum lipid panel, basic metabolic panel (BMP), and blood pressure measurements. Demographic data, family history, and current medication information were also collected.
RESULTS: A total of 249 men participated in the program from February 2017-April 2018, of which 218 (87.6%) were AA. Median PSA was 1.07 (range 0.13-28.89 ng/ml), median age was 54.9, and 5.2% of men had an abnormal DRE. Testing resulted in 36 referrals to Urology for elevated PSA or abnormal DRE (83% attendance), 21 referrals to Internal Medicine (85% attendance), 27 referrals to Family Medicine (33% attendance), and 7 referrals to Emergency Medicine for hypertensive crises (100% attendance). Subsequent new diagnoses included hypertension, diabetes, diabetic ketoacidosis, chronic obstructive pulmonary disease, heart failure, metastatic colon cancer, and metastatic renal cell carcinoma.
CONCLUSIONS: The P-SCAN program represents an opportunity for comprehensive health care in a high-risk, low-income population. We demonstrate the ability to provide health-literacy appropriate education regarding screening in a group characterized by minimal exposure to primary healthcare. Community-based comprehensive screening offers a unique opportunity to improve overall health outcomes in disadvantaged populations outside of traditionally singular diagnoses. In high-risk populations targeted by these plans, overall health status may be improved through implementation of similar programs.
Source of Funding: Astellas
MP44-19 ADHERENCE TO A BEHAVIOR MODIFICATION INTERVENTION FOR PROSTATE CANCER: THE MEN'S EATING AND LIVING (MEAL) STUDY (CALGB 70807 [ALLIANCE])
J Parsons*, Loki Natarajan, John Pierce, La Jolla, CA; James Mohler, Buffalo, NY; Electra Paskett, Columbus, OH; Cheryl Rock, La Jolla, CA; James Marshall, Buffalo, NY INTRODUCTION AND OBJECTIVES: Clinical guidelines endorsing lifestyle-based therapies for prostate cancer survivors are based on expert opinion and observational studies. There are limited data on the efficacy of structured, behavior-based interventions to affect beneficial change in urological cancers.
METHODS: As part of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]), we assessed adherence to an intervention promoting vegetable intake in men on active surveillance for prostate cancer. Eligible patients were randomized (1:1) to a validated, telephone-based counseling intervention or a control condition in which they received printed materials from the Prostate Cancer Foundation (PCF) recommending consumption of a healthy diet. Intervention participants were assigned to a counselor who encouraged consumption of ! 7 daily vegetable-fruit servings. During follow-up, an independent team evaluated the diets of participants by telephone interview using the Nutrition Data Systems for Research (NDS-R, current version 2010, University of Minnesota Nutrition Coordinating Center, University of Minnesota, Minneapolis, MN). Fasting blood samples were collected at baseline, 12 months, and 24 months and analyzed for plasma carotenoids-biomarkers of vegetable intake and putative anti-carcinogens-using high-performance liquid chromatography. Changes in mean daily intakes of total vegetables, crucifers, tomato products, and fat and in plasma carotenoid concentrations were assessed using two-sample t-tests.
RESULTS: Baseline characteristics were balanced across the two study arms. Mean (SD) age was 63.5 (6.4) years and PSA 4.9 (2.1) ng/mL. Fifty (11%) participants were African-American. There were no significant differences between groups for age, race/ethnicity, region, time elapsed since prostate cancer diagnosis, PSA, clinical stage, or tumor grade. Compared to control, the intervention significantly increased from baseline-and sustained through 24-month follow-upvegetable (þ71% vs. þ11% servings/day, p < 0.0001), crucifer (þ222% vs. þ8% servings/day, p < 0.0001), carotenoid (þ114% vs. þ4% mcg/day, p < 0.0001), and lycopene (þ130% vs. -10% mcg/ day, p < 0.0001) consumption and blood carotenoid levels (þ24% vs. þ10% µmol/L, p [ 0.01).
CONCLUSIONS: The MEAL Study is the first randomized clinical trial of a behavior modification intervention in prostate cancer survivors. These data demonstrate that scalable, robust, lifestylefocused behavior change is feasible in a urological cancer population.
INTRODUCTION AND OBJECTIVES:
Bladder cancer is a leading cause of cancer death in the United States. Radical cystectomy (RC) is associated with significant morbidity and quality of life impairment, hence, decision making process requires robust patient counseling. Refusal of RC in index patients who are recommended the procedure remains understudied.
We aimed to investigate the National Cancer Database (NCDB) to delineate factors associated with refusal of RC, subsequent treatment decisions and the effect of these decisions on overall survival (OS).
METHODS: We queried the NCDB for patients with localized, non-metastatic muscle-invasive bladder cancer (MIBC), cT2-T4M0. Patients who were recommended RC by treating physician but refused surgery and refusal was noted in records were further identified. Patients were excluded from the analysis if surgery was not part of the planned treatment course, surgery was not recommended or if survival data was unknown.
